Blockade of CD28 or CD40LG, including but not limited to genetic or pharmacologic means, mAbs and chimeric antigen receptor-based therapy, will suppress tumor growth and BM infiltration, thereby offering a novel therapeutic approach for the treatment of T-ALL. Here, CD28 is linked to neoplasm.